A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan Academic Article Article uri icon

Overview

MeSH Major

  • Adenocarcinoma
  • Biomarkers, Tumor
  • Genomic Instability
  • Pancreatic Neoplasms
  • Precision Medicine

abstract

  • Future development of this compound cannot be recommended as monotherapy in this disease.

publication date

  • August 26, 2002

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1093/annonc/mdf173

PubMed ID

  • 12176785

Additional Document Info

start page

  • 1067

end page

  • 71

volume

  • 13

number

  • 7